Home LiteratureArticle Details
PMID: 23291930 Published · ppublish English Journal Article Review

Correlates of protection to influenza virus, where do we go from here?

Human vaccines & immunotherapeutics ·Vol. 9 ·No. 2 ·2013-02-00 ·Pages 405-8

Cox RJ

Abstract

Influenza vaccination is the cornerstone of prophylaxis. The regulatory authorities currently annually license vaccines based on serum antibodies directed toward the major surface glycoprotein haemagglutinin (HA). The most commonly used serological test, the haemagglutination inhibition (HI) assay utilizes red blood cells, which show considerable biological variation. There is a need for validated, standardized assays to reduce laboratory variation steps that are currently being taken by the regulatory agencies. Here we examine the historical evidence for defining the HI titer ≥ 40 as a surrogate correlate of protection and examine alternative assays. Moreover, the immune response to influenza is multifacated and there are probably multiple correlates of protection. We conclude there is a need for detailed immunological analysis including kinetic studies and head to head comparison of vaccines by a range of immunological assays to further define correlates of protection.

Keywords
correlate protection influenza
MeSH Terms
Antibodies, Viral/blood Biomarkers/analysis Humans Immunoassay/methods,standards Influenza Vaccines/administration & dosage,immunology Influenza, Human/immunology,prevention & control Reproducibility of Results Statistics as Topic
Chemicals
Antibodies, Viral Biomarkers Influenza Vaccines
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Cox Rebecca J
Department of Clinical Science; University of Bergen; Haukeland University Hospital; Bergen, Norway; Department of Research & Development; Haukeland University Hospital; Bergen, Norway.
References (29)
29 references, click to expand
  1. [New drugs and European procedures of approval. The European Agency for the Evaluation of Medicinal Products' role].
    Ugeskr Laeger. 2003 Apr 14;165(16):1648-9 PMID: 12756819
  2. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model.
    BMC Med Res Methodol. 2010 Mar 08;10:18 PMID: 20210985
  3. Interpretation of responses and protective levels of antibody against attenuated influenza A viruses using single radial haemolysis.
    J Hyg (Lond). 1984 Oct;93(2):301-12 PMID: 6389697
  4. Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study.
    Vaccine. 2007 May 16;25(20):4056-63 PMID: 17412461
  5. Protective efficacy of live-attenuated influenza vaccine (multivalent, Ann Arbor strain): a literature review addressing interference.
    Expert Rev Vaccines. 2011 Aug;10(8):1131-41 PMID: 21854309
  6. Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model.
    Influenza Other Respir Viruses. 2011 Nov;5(6):426-37 PMID: 21668670
  7. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children.
    Clin Vaccine Immunol. 2008 Jul;15(7):1042-53 PMID: 18448618
  8. Peak frequencies of circulating human influenza-specific antibody secreting cells correlate with serum antibody response after immunization.
    Vaccine. 2010 Apr 30;28(20):3582-7 PMID: 20298818
  9. Reproducibility of serology assays for pandemic influenza H1N1: collaborative study to evaluate a candidate WHO International Standard.
    Vaccine. 2012 Jan 5;30(2):210-7 PMID: 22100887
  10. T cell responses are better correlates of vaccine protection in the elderly.
    J Immunol. 2006 May 15;176(10):6333-9 PMID: 16670345
  11. Enhancing the reproducibility of serological methods used to evaluate immunogenicity of pandemic H1N1 influenza vaccines-an effective EU regulatory approach.
    Vaccine. 2012 Jun 8;30(27):4113-22 PMID: 22446639
  12. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children.
    Pediatr Infect Dis J. 2011 Dec;30(12):1081-5 PMID: 21983214
  13. T-helper 1 cells elicited by H5N1 vaccination predict seroprotection.
    J Infect Dis. 2012 Jul 15;206(2):158-66 PMID: 22551811
  14. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans.
    Nat Med. 2012 Jan 29;18(2):274-80 PMID: 22286307
  15. Comparison of influenza serological techniques by international collaborative study.
    Vaccine. 1994 Feb;12(2):167-74 PMID: 8147099
  16. Granzyme B: Correlates with protection and enhanced CTL response to influenza vaccination in older adults.
    Vaccine. 2009 Apr 21;27(18):2418-25 PMID: 19368783
  17. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis.
    Lancet Infect Dis. 2012 Jan;12(1):36-44 PMID: 22032844
  18. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels.
    Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3877-82 PMID: 19237568
  19. Cytotoxic T-cell immunity to influenza.
    N Engl J Med. 1983 Jul 7;309(1):13-7 PMID: 6602294
  20. Reproducibility of serologic assays for influenza virus A (H5N1).
    Emerg Infect Dis. 2009 Aug;15(8):1252-9 PMID: 19751587
  21. Determinants of immunity to influenza infection in man.
    Br Med Bull. 1979 Jan;35(1):69-75 PMID: 367490
  22. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses.
    J Hyg (Lond). 1972 Dec;70(4):767-77 PMID: 4509641
  23. A(H1N1)pdm09 vaccination of health care workers: improved immune responses in low responders following revaccination.
    J Infect Dis. 2012 Dec 1;206(11):1660-9 PMID: 22969149
  24. Haemagglutination-inhibiting antibody to influenza virus.
    Dev Biol (Basel). 2003;115:63-73 PMID: 15088777
  25. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial.
    Vaccine. 2011 Oct 19;29(45):8049-59 PMID: 21864624
  26. Natural or vaccine-induced antibody as a predictor of immunity in the face of natural challenge with influenza viruses.
    Epidemiol Infect. 1989 Apr;102(2):325-33 PMID: 2703026
  27. An early humoral immune response in peripheral blood following parenteral inactivated influenza vaccination.
    Vaccine. 1994 Aug;12(11):993-9 PMID: 7975853
  28. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine.
    Virus Res. 2004 Jul;103(1-2):91-5 PMID: 15163495
  29. Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin.
    J Med Virol. 2003 Jul;70(3):391-8 PMID: 12767002
Article Info
Journal
Human vaccines & immunotherapeutics
Abbr.
Hum Vaccin Immunother
ISSN
2164-554X
DOI
10.4161/hv.22908
Published
2013-02-00
Epub
2013-00-04
Pages
405-8
Language
English
Region
United States
NLM ID
101572652
PMCID
PMC3859764
Subset
IM
External Links
PubMed source DOI: 10.4161/hv.22908 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2